**Insulin signaling in skeletal muscle of HIV-infected patients in response to endurance and strength training**

Christa Broholm¹, Neha Mathur¹, Thine Hvid¹, Thomas Sahl Grøndahl¹, Christian Frøsig², Bente Klarlund Pedersen¹ & Birgitte Lindegaard¹

¹ Department of Infectious Diseases, Centre of Inflammation and Metabolism, Rigshospitalet, Copenhagen, Denmark
² Section of Molecular Physiology, The August Krogh Centre, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark

**Abstract**

Human immunodeficiency virus (HIV)-infected patients with lipodystrophy have decreased insulin-stimulated glucose uptake. Both endurance and resistance training improve insulin-stimulated glucose uptake in skeletal muscle of HIV-infected patients, but the mechanisms are unknown. This study aims to identify the molecular pathways involved in the beneficial effects of training on insulin-stimulated glucose uptake in skeletal muscle of HIV-infected patients.

Eighteen sedentary male HIV-infected patients underwent a 16 week supervised training intervention, either resistance or strength training. Euglycemic–hyperinsulinemic clamps with muscle biopsies were performed before and after the training interventions. Fifteen age- and body mass index (BMI)-matched HIV-negative men served as a sedentary baseline group. Phosphorylation and total protein expression of insulin signaling molecules as well as glycogen synthase (GS) activity were analyzed in skeletal muscle biopsies in relation to insulin stimulation before and after training.

HIV-infected patients had reduced basal and insulin-stimulated GS activity (%fractional velocity, [FV]) as well as impaired insulin-stimulated Akt thr308 phosphorylation. Despite improving insulin-stimulated glucose uptake, neither endurance nor strength training changed the phosphorylation status of insulin signaling proteins or affected GS activity. However; endurance training markedly increased the total Akt protein expression, and both training modalities increased hexokinase II (HKII) protein. HIV-infected patients with lipodystrophy have decreased insulin-stimulated glucose uptake in skeletal muscle and defects in insulin-stimulated phosphorylation of Akt thr308. Endurance and strength training increase insulin-stimulated glucose uptake in these patients, and the muscular training adaptation is associated with improved capacity for phosphorylation of glucose by HKII, rather than changes in markers of insulin signaling to glucose uptake or glycogen synthesis.

**Introduction**

Human immunodeficiency virus (HIV)-infected patients are treated with highly active combination antiretroviral therapy (HAART), which as a side effect leads to development of lipodystrophy. HIV-associated lipodystrophy is characterized by a loss of subcutaneous fat and relative gain in visceral fat leading to severe metabolic disturbances like insulin resistance (Grinspoon and Carr 2005).

Patients with HIV-associated lipodystrophy show both impaired insulin-stimulated whole-body oxidative glucose disposal (Behrens et al. 2002) and impaired nonoxidative glucose disposal (van der Valk et al. 2001; Behrens et al. 2002; Andersen et al. 2003; Haugaard et al. 2005).
indicating peripheral insulin resistance. Defective oxidative glucose disposal in HIV-infected patients is caused by impaired glucose transport and phosphorylation (Behrens et al. 2002), suggesting defects in glucose phosphorylating enzymes like hexokinase II (HKII). In both normal and diabetic subjects, storage of glucose as muscle glycogen accounts for the majority of the nonoxidative glucose disposal and for most of the total body glucose uptake during insulin infusion (Shulman et al. 1990). Therefore, the reduced nonoxidative glucose disposal in patients with HIV-associated lipodystrophy is believed to reflect impaired glycogen synthesis (Andersen et al. 2003; Haugaard et al. 2005), and molecular defects at the level of glycogen synthase (GS), glycogen synthase kinase (GSK)-3, and Akt have been demonstrated in skeletal muscle of patients with HIV-associated lipodystrophy (Haugaard et al. 2005).

It is well established that physical activity is beneficial for improving insulin sensitivity as individuals who maintain a physically active lifestyle are less likely to develop insulin resistance, impaired glucose tolerance, and type 2 diabetes (Hawley 2004; Pedersen 2006). Based on studies in healthy and diabetic subjects, the mechanisms underlying the beneficial effects of exercise on insulin sensitivity in muscle seem to be associated with changes in protein composition of skeletal muscle with relevance to the actions of insulin (e.g., glucose transporter-4 [GLUT4], HKII, insulin receptor [IR], Akt, TBC1D4 [previously called AS160], and GS) rather than major changes in insulin signaling capacity as determined by phosphorylation status or enzyme activities (Henriksen 2002; Zierath 2002; Holten et al. 2004; Frosg et al. 2007).

Only few studies have investigated the effect of training on insulin sensitivity in patients with HIV-associated lipodystrophy, and conflicting results exist (Jones et al. 2001; Smith et al. 2001; Yarasheski et al. 2001; Thoni et al. 2002; Driscoll et al. 2004; Dolan et al. 2006; Robinson et al. 2007). We recently performed a study investigating the effect of 16 weeks supervised endurance and resistance training on insulin sensitivity, measured by the euglycemic–hyperinsulinemic clamp technique with tracer infusion, on male HIV-infected patients with lipodystrophy. At baseline, HIV-infected patients had lower insulin sensitivity than healthy HIV-negative men, but both training modalities markedly increased peripheral insulin sensitivity (Lindegaard et al. 2008). Muscle biopsies were obtained during the euglycemic–hyperinsulinemic clamp performed in HIV-infected patients before and after both training interventions, and in the present study we aimed to define the possible intracellular pathways mediating the beneficial effects of endurance and resistance exercise on peripheral insulin sensitivity in HIV-infected patients with lipodystrophy.

Research Design and Methods

Participants

Thirty-nine HIV-infected men were recruited from the outpatient clinic of the Department of Infectious Diseases (Rigshospitalet, Copenhagen, Denmark). The detailed inclusion and exclusion criteria were previously described (Lindegaard et al. 2008). In short, the patients enrolled in the study were untrained according to Astrand et al. (1973), had received HAART treatment for at least 3 month prior to the study, and were defined as lipodystrophic. Of 39 patients recruited, 24 fulfilled the inclusion criteria, but four declined to participate and two withdrew from the training study because of severe back problems and psychiatric problems. Thus, 18 HIV-infected patients completed the study.

Fifteen age- and VO_{2max}-matched HIV-negative healthy men served as controls for baseline measurement. Written and informed consent was obtained from all participants according to the requirements from the local ethical committee (KF 01-262/04) and the Helsinki Declaration II.

Study protocol

All HIV-infected patients were randomized to either 16 weeks of endurance or strength training. Before, after 8 and after 16 weeks of training, HIV-infected patients performed a VO_{2max} test on cycle ergometer and a three-repetition maximum (3-RM) strength test during six exercises: leg curl, pull-down, seated leg press, chest, press, seated rows, and leg extension. At baseline and after 16 weeks a euglycemic–hyperinsulinemic clamp with stable isotope infusion was performed as described previously (Lindegaard et al. 2008). Muscle biopsies were obtained before the clamp and 150 min after start of the clamp in musculus vastus lateralis using the Bergstrom biopsy needle technique (Bergstrom 1975). The participants were randomized to endurance training or strength training after the clamp procedure. All training sessions were supervised, and the subjects’ heart rate was continuously monitored. The subjects trained three times per week for 16 weeks. The endurance training protocol consisted of eight different programs with 35 min of interval training. The first 8 weeks, the mean intensity was targeted at 65% of VO_{2max} and the last 8 weeks, it was 75% of VO_{2max}. The strength training consisted of eight exercises (leg curl, pull-down, seated leg press, chest press, seated rows, leg extension, abdominal crunch, and back extension) in resistance training machines for 45–60 min. The resting intervals were 60–120 sec. The number of repetitions and sets changed every week. Compliance was noted at each training day, and if subjects missed a training day, a makeup was made.
Muscle lysate preparation

Muscle tissue was freeze-dried and dissected free of visual blood, fat, and connective tissues. Depending on weight, muscle lysate was then prepared by the addition of 0.4–1.0 mL homogenization buffer (50 mmol/L Hepes, 10% glycerol, 20 mmol/L sodium pyrophosphate, 150 mmol/L sodium chloride, 1% NP-40, 20 mmol/L β-glycerophosphate, 10 mmol/L sodium fluoride, 2 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L ethylenediaminetetraacetic acid, 1 mM ethylene glycol tetraacetic acid, 10 μg/mL aprotinin, 10 μg/mL leupeptin, 2 mmol/L sodium orthovanadate, 3 mmol/L benzamidine) to the freeze-dried muscle tissue. The muscle tissue was then homogenized using cooled racks in a TissueLyser (Qiagen, Valencia, CA) for 1 min at 30 Hz followed by 15 min incubation on ice. The homogenization and incubation on ice were repeated two or three times depending on the degree of homogenization of the tissue. Homogenates were then rotated end over end for 1 h at 4°C and centrifuged at 16 000 g at 4°C for 25 min. The supernatant protein concentrations were determined with a Bio-Rad DC kit (Bio-Rad, Hercules, CA) using bovine serum albumin (BSA) as standard. All determinations were done in triplicate.

Western blotting

Protein expression and protein phosphorylation were studied in muscle tissue homogenates by Sodium dodecyl sulfate-polyacrylamide gel electrophoresis using 4–12% Bis-Tris gels (Invitrogen, Taastrup, Denmark) and western blotting using polyvinylidene difluoride membranes (GE Healthcare, Little Chalfont, U.K.). The membranes were blocked for 1 h at room temperature in either 5% skim milk or 5% BSA and subsequently incubated overnight at 4°C with antibodies against AS160Thr642 (#4288; Cell Signaling, Danvers, MA), AS160 (# 07-741; Upstate, Millipore, Billerica, MA), AktThr308 (#4056; Cell Signaling), Akt (#9272; Cell Signaling), GSK-3β (#9315; Cell Signaling), GSK-3β(ser9)#323; Cell signaling), HXKII (#6521; Santa Cruz, CA) and GS (#3893; Cell Signaling). For detection of GS site 3a+b (ser640 and ser644 cophosphorylation), an antibody was raised against the peptide PYPRPPAspVPPSpPSLSR as described (Hojlund et al. 2003). After overnight incubation, the membranes were incubated for 1 h at room temperature with a horseradish peroxidase-conjugated secondary antibody (DAKO, Glostrup, Denmark). Protein bands were detected using Supersignal West Femto chemiluminescence (Pierce, Rockford, IL) and quantified using a charge-coupled device image sensor (ChemiDocXRS; Bio-Rad) and software (Quantity One; Bio-Rad). To check for even loading and transfer, all membranes were stained with reactive brown (Sigma-Aldrich, St. Louis, MO).

GS activity

GS activity was measured in duplicates in muscle homogenates by using a unifilter 350 microtiter plate assay (Whatman, Frisenette, Ebeltoft, Denmark) as described by Thomas et al. 1968.

Statistics

All analyses were performed using SAS software version 9.1.3. Data were evaluated using two-way analysis of variance (ANOVA) with repeated measures for effect of clamp and group (Figs. 1 and 2) or for effect of clamp and training (Figs. 4 and 5). The ANOVA analyses were performed separately for the endurance training and strength training groups. Student’s t-test with bonferroni correction was used as post hoc test. The residuals obtained from the ANOVA models were evaluated, and the model was only accepted if the residuals were normally distributed. If data were not normally distributed, a logarithmic transformation was performed. Changes (Δ) from basal to insulin-stimulated values were compared between groups by unpaired t-test (Figs. 1, 2, and 4, 5). Changes in total protein expression before and after training were evaluated by paired t-test (Fig. 3). Data are presented as means ± SE unless otherwise indicated. A level of P < 0.05 was accepted as statistically significant.

Results

The general adaptations to the present training regimen have been published previously (Lindegaard et al. 2008). In brief, HIV-infected patients were included on the basis of moderate lipoatrophy and were characterized by reduced limb fat mass, increased percentage of fat in the trunk, and an increased trunk-to-limb fat ratio. HIV-infected patients had increased blood plasma insulin concentrations, increased homeostatic model assessment for insulin resistance (HOMA-IR), and increased glucose and insulin area under the curves during an oral glucose tolerance test (OGTT) compared to controls (Table 1). During the euglycemic–hyperinsulinemic clamp, insulin-stimulated glucose uptake and changes (Δ) from basal to insulin-stimulated glucose uptake were lower in HIV-infected patients compared to controls (Table 1). Insulin-mediated glucose uptake was improved by both endurance training and strength training (Table 2). Only strength training increased total lean body mass (2.5 kg) and decreased total fat mass (3.3 kg).
Figure 1. Phosphorylation level of insulin signaling molecules in skeletal muscle of 18 human immunodeficiency virus (HIV)-infected patients and 15 HIV-negative individuals at basal levels and after insulin infusion. (A) Phosphorylation of Akt\textsuperscript{thr308} related to total Akt protein expression, (B) Phosphorylation of AS160\textsuperscript{thr642} related to total AS160 protein expression, (C) Phosphorylation of GSK3\textsuperscript{β}ser9 related to total GSK3\textsuperscript{β} protein expression, (D) Phosphorylation of glycogen synthase GS at site 3a+b related to total GS protein expression, (E) Representative western blots are shown: Protein bands are from the same subject before and after insulin stimulation. The black line indicates that the samples were not loaded adjacent, but for each subject they were loaded on the same gel. Data are means ± SE. *P < 0.05 (Post hoc paired t-test comparing insulin values to basal values in the same group), #P < 0.05 unpaired t-test comparing changes (Δ) from basal to insulin stimulation between groups.
Phosphorylation of insulin signaling molecules in skeletal muscle of HIV-infected patients and controls

In response to insulin stimulation, phosphorylation of Akt<sub>thr308</sub> (P < 0.0001), AS160<sub>thr642</sub> (P < 0.001), and GSK3<sub>b</sub><sup>ser9</sup> (P < 0.05) increased in skeletal muscle of both HIV-infected patients and controls (Fig. 1). Furthermore, insulin stimulation resulted in a decreased phosphorylation of GS site 3a<sup>b</sup> in skeletal muscle of both HIV-infected patients and controls (P < 0.0001). The changes (Δ) from basal to insulin-stimulated phosphorylation of Akt<sub>thr308</sub> were lower in HIV-infected patients compared to controls (P < 0.05). There were no differences in total protein expression of Akt, AS160, GS, and GSK3 between HIV-infected patients and controls.

Activity of GS in skeletal muscle of HIV-infected patients and controls

In response to insulin stimulation, GS activity expressed as the I form% (independent form) and FV% significantly increased in skeletal muscle of both HIV-infected patients and controls (both, P < 0.0001) (Fig. 2). GS activity expressed as FV% was significantly lower in skeletal muscle of HIV-infected patients (P < 0.01) both during basal conditions and after insulin stimulation. As expected, total GS activity was not affected by either insulin or group.

Protein contents of Akt, AS160, HKII, GS, and GSK3 in response to endurance and strength training of HIV-infected patients

After endurance training, protein content of Akt (P < 0.001) and HKII (P < 0.05) was increased, whereas the protein content of GSK3, AS160, and GS was unaltered (Fig. 3). Strength training lead to an increased expression of HKII (P < 0.05), but did not affect protein level of Akt, GSK3, AS160, or GS.
Effect of insulin, endurance group: \( P < 0.0001 \)
Effect of training, endurance group: N.S.
Effect of insulin, strength group: \( P < 0.0001 \)
Effect of training, strength group: N.S.

Effect of insulin, endurance group: N.S.
Effect of training, endurance group: N.S.
Effect of insulin, strength group: \( P < 0.001 \)
Effect of training, strength group: N.S.

Figure 4. Phosphorylation level of insulin signaling molecules in skeletal muscle of HIV-infected patients before and after 16 weeks of endurance (\( n = 8 \)) and strength training (\( n = 10 \)) at basal levels and after insulin infusion. (A) Phosphorylation of Akt\(^{thr308} \), (B) Phosphorylation of AS160\(^{thr642} \) related to total AS160 protein expression, (C) Phosphorylation of GSK3\(^β^{ser9} \) related to total GSK3\(^β \) protein expression, (D) Phosphorylation of GS at site 3a+b related to total GS protein expression, (E) Representative western blot is shown: Protein bands are from the same subject before/after endurance and strength training, respectively. The black line indicates that the basal samples and insulin samples were not loaded adjacent, but for each subject they were loaded on the same gel. Data are means ± SE. *\( P < 0.05 \) (post hoc paired t-test comparing insulin values to basal values in the same group).
Phosphorylation of insulin signaling molecules in response to endurance and strength training of HIV-infected patients

Insulin stimulation increased phosphorylation of Akt$^{thr308}$ in muscle biopsies obtained before and after training ($P < 0.0001$ in both training groups) (Fig. 4). Phosphorylated Akt$^{thr308}$ was not related to total Akt, as the protein expression levels of Akt increased with endurance training (Fig. 3). Phosphorylation of AS160$^{thr462}$ and GSK3$^{beta9}$ increased significantly in response to insulin in muscle biopsies obtained before and after strength training (both, $P < 0.001$), but in the group undergoing endurance training we found no statistical effect of insulin stimulation on the phosphorylation levels of AS160$^{thr462}$ or GSK3$^{beta9}$. Phosphorylation of GS site $3a+b$ decreased significantly in response to insulin stimulation in muscle biopsies obtained before and after both endurance training ($P < 0.01$) and strength training ($P < 0.0001$). There was no effect of training at the investigated phosphorylation sites.

Activity of GS in response to endurance and strength training of HIV-infected patients

In response to insulin stimulation, GS activity expressed as the I form$%$ and FV$%$ increased in muscle biopsies obtained before and after both training interventions ($P < 0.0001$, both proteins and both training groups) (Fig. 5). Their activity levels were unaffected by the exercise interventions. Total GS activity was not affected by insulin stimulation, but there was an overall effect of endurance exercise ($P < 0.05$).

Discussion

We have previously shown that lipodystrophic patients with HIV have a markedly decreased insulin-stimulated glucose disposal compared to nonlipodystrophic HIV-negative controls, but that supervised, intensive endurance and strength training in HIV-infected patients can restore the insulin-stimulated glucose uptake (Lindegaard et al. 2008). By using muscle biopsies from the same cohort, this study further investigates the molecular mechanisms underlying the decreased insulin sensitivity in skeletal muscle of HIV-infected patients and the possible proteins involved in the beneficial effects of exercise training on insulin sensitivity. We found that lipodystrophic HIV-infected patients suffered from defects in insulin-stimulated Akt$^{thr308}$ phosphorylation. Endurance exercise training in HIV-infected patients markedly increased basal protein expression of Akt and HKII, whereas strength training increased only basal protein expression of HKII. The findings altogether suggest that this training adaptation is associated with improved capacity for phosphorylation of glucose by HKII, rather than changes in markers of insulin signaling to glucose uptake or glycogen synthesis.

Previous studies have shown a beneficial effect of both endurance and strength training on glucose metabolism in HIV-infected patients (Jones et al. 2001; Smith et al. 2001; Yarasheski et al. 2001; Thoni et al. 2002; Driscoll et al. 2004; Dolan et al. 2006; Robinson et al. 2007), but this is the first study to investigate the molecular mechanisms involved. Thus, the strength of this study is the combination of a clinical study involving a highly specific patient group, two different supervised intensive training
### Table 1. Baseline characteristics for HIV patients and healthy controls.

|                           | Endurance group (n = 8) | Strength group (n = 10) | Healthy controls (n = 15) | P-value, endurance group versus strength group | P-value, HIV patients versus healthy |
|---------------------------|-------------------------|-------------------------|---------------------------|-----------------------------------------------|-------------------------------------|
| Age (year)                | 53.1 (8.4)              | 45.9 (8.0)              | 47.5 (6.1)                | 0.09                                          | 0.5                                 |
| Duration of HIV infection (year) | 14 (7.4)               | 16 (12.2)              |                           |                                               |                                     |
| Duration of antiretroviral therapy (year) | 9.0 (4.6)               | 10.3 (3.8)              |                           |                                               |                                     |
| Antiretroviral use        |                         |                         |                           |                                               |                                     |
| NNRTI-based HAART/PI-based HAART/NNRTI-based HAART regime, n. | 3/5/0                   | 4/5/1                   |                           |                                               |                                     |
| Current NRTI use, n. (%)  | 8 (100)                 | 10 (100)                |                           |                                               |                                     |
| Lamivudine (%)            | 6 (75)                  | 9 (90)                  |                           |                                               |                                     |
| Zidovudine (%)            | 4 (50)                  | 6 (60)                  |                           |                                               |                                     |
| Stavudine (%)             | 0 (0)                   | 1 (10)                  |                           |                                               |                                     |
| Tenofovir/emtricitabine (%) | 3 (37.5)              | 1 (10)                  |                           |                                               |                                     |
| Abacavir (%)              | 3 (37.5)                | 4 (40)                  |                           |                                               |                                     |
| Current PI use, n. (%)    | 5 (62.5)                | 6 (60)                  |                           |                                               |                                     |
| Current NNRTI use, n. (%) | 3 (37.5)                | 5 (50)                  |                           |                                               |                                     |
| VO2max (LO2/min)          | 2.5 (0.4)               | 2.2 (0.5)               | 2.5 (0.6)                 | 0.22                                          | 0.3                                 |
| Body composition          |                         |                         |                           |                                               |                                     |
| Body mass index (kg/m2)   | 24.0 (3.1)              | 23.4 (2.5)              | 23.7 (1.9)                | 0.65                                          | 0.98                                |
| Weight (kg)               | 78.4 (10.0)             | 72.5 (9.2)              | 76.9 (7.9)                | 0.21                                          | 0.5                                 |
| Trunk fat percentage (%)  | 70.3 (4.4)              | 71.5 (8.2)              | 56.1 (5.2)                | 0.71                                          | <0.0001                             |
| Limb fat mass (kg)        | 3.9 (1.2)               | 3.4 (1.7)               | 6.2 (1.5)                 | 0.45                                          | <0.0001                             |
| Limb fat percentage (%)   | 26.2 (4.1)              | 24.8 (8.0)              | 40.2 (4.9)                | 0.66                                          | <0.0001                             |
| Trunk-to-limb fat ratio   | 2.8 (0.60)              | 3.3 (0.61)              | 1.4 (0.29)                | 0.38                                          | <0.001                              |
| Lean mass (kg)            | 59.9 (5.5)              | 56.2 (6.4)              | 58.2 (5.2)                | 0.18                                          | 0.9                                 |
| Insulin (µmol/liter) median (interquartile ranges) | 42 (30–65)              | 47 (39–75)              | 26 (18–31)                | 0.29                                          | 0.0001                              |
| HOMA-IR median (interquartile ranges) | 1.7 (1.4–2.6)          | 2.0 (1.4–2.9)           | 1.1 (0.76–0.3)            | 0.73                                          | 0.002                               |
| Insulin sensitivity       |                         |                         |                           |                                               |                                     |
| $R_D$ (µmol glucose/kg*min) |                         |                         |                           |                                               |                                     |
| Basal                    | 14.3 (0.49)             | 14.1 (1.6)              | 11.8 (2.0)                | 0.84                                          | 0.0002                              |
| Clamp                    | 5.9 (2.0)               | 6.8 (1.8)               | 4.0 (2.5)                 | 0.35                                          | 0.004                               |
| $\Delta R_D$             | 8.3 (2.06)              | 7.3 (2.1)               | 7.8 (1.9)                 | 0.34                                          | 0.9                                 |
| $R_D$ (µmol glucose/kg*min) |                         |                         |                           |                                               |                                     |
| Basal                    | 14.3 (0.49)             | 14.1 (1.6)              | 11.8 (2.0)                | 0.84                                          | 0.0002                              |
| Clamp                    | 43.0 (10.6)             | 38.0 (9.2)              | 48.6 (8.4)                | 0.3                                           | 0.0015                              |
| $\Delta R_D$             | 28.8 (10)               | 23.8 (9.4)              | 36.81 (7.14)              | 0.31                                          | 0.0015                              |

Baseline subject characteristics are previously described in Lindegaard et al. (2008). Data are presented as mean (SD) or when indicated as median (interquartile ranges), when data were log transformed. Baseline comparisons for the HIV patients are all $P > 0.05$ by t-test. NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; HOMA-IR, homeostatic model assessment for insulin resistance; $R_D$, rate of appearance; $R_D$, rate of disappearance of glucose during an euglycemic–hyperinsulinemic clamp performed in both HIV patients and healthy control; $\Delta R_D$, differences between clamp and basal values.
regulated Akt activity so we analyzed downstream Akt signaling. Akt signaling in skeletal muscle leads to phosphorylation of GSK3\(^{\text{ser9}}\), whereby the GSK enzyme is inactivated (Welsh and Proud 1993). This leads to dephosphorylation of GS site 3a+b, which subsequently activates the GS enzyme (McManus et al. 2005). We found no changes in the phosphorylation sites of these proteins or in the activity of GS following insulin stimulation. Thus, we have no indications that an increased Akt protein expression facilitated insulin signaling to glycogen synthesis. Neither did we observe changes in the phosphorylation state of AS160\(^{\text{ser422}}\) following the endurance training period. Thus, we did not identify a pathway whereby increased Akt protein expression would enhance insulin-stimulated glucose uptake. Interestingly, total GS activity increased with endurance training as observed both with and without insulin stimulation. This adaptation is a consistent result of changes in Akt activation and downstream signaling.

We observed an increased expression of Akt in skeletal muscle of HIV-infected patients following 16 weeks of endurance training. Of note, our endurance exercise protocol consisted of interval training and it is possible that steady state endurance exercise training would not have this effect on Akt expression. An increased protein expression of Akt following training has previously been observed in older subjects with and without Type 2 diabetes (Christ-Roberts et al. 2004) and in young healthy men (Frosig et al. 2007).

The increased Akt protein expression was not accompanied by changes in the phosphorylation status of Akt\(^{\text{thr308}}\). Nonetheless, an increased Akt protein expression could facilitate enhanced downstream Akt signaling reflected by changes in Akt activity without changes in phosphorylation of Akt\(^{\text{thr308}}\) (Frosig et al. 2007). Unfortunately, due to limited tissue availability, we were unable to measure Akt activity so we analyzed downstream Akt signaling. Akt signaling in skeletal muscle leads to phosphorylation of GSK3\(^{\text{ser9}}\), whereby the GSK enzyme is inactivated (Welsh and Proud 1993). This leads to dephosphorylation of GS site 3a+b, which subsequently activates the GS enzyme (McManus et al. 2005). We found no changes in the phosphorylation sites of these proteins or in the activity of GS following insulin stimulation. Thus, we have no indications that an increased Akt protein expression facilitated insulin signaling to glycogen synthesis. Neither did we observe changes in the phosphorylation state of AS160\(^{\text{ser422}}\) following the endurance training period. Thus, we did not identify a pathway whereby increased Akt protein expression would enhance insulin-stimulated glucose uptake. Interestingly, total GS activity increased with endurance training as observed both with and without insulin stimulation. This adaptation is a consistent result of changes in Akt activation and downstream signaling.

**Table 2.** The effect of endurance and strength training on insulin sensitivity in HIV-infected patients with lipodystrophy.

|                      | Endurance |         |         |         | Strength |         |         |
|----------------------|-----------|---------|---------|---------|----------|---------|---------|
|                      | Pretraining | Posttraining | % difference | \(P\)-value | Pretraining | Posttraining | % difference | \(P\)-value |
| Glucose \(R_d\) (µmol glucose/kg body weight × min) | 43.03 (10.6) | 49.7 (10) | 15.6 | 0.005 | 38.0 (9.2) | 47.6 (15) | 25 | 0.003 |
| \(\Delta R_d\) | 28.8 (10) | 35.3 (10.5) | 22.7 | 0.008 | 23.8 (9.4) | 34.0 (15) | 42.6 | 0.002 |

Effect of training on insulin sensitivity, as previously described in Lindegaard et al. (2008). Glucose \(R_d\) (glucose rate of disappearance), expressed as micromoles per kilogram body weight per minute. Data are presented as mean (SD).

regimes and euglycemic–hyperinsulinemic clamps with molecular analyses in muscle biopsies.

Upon insulin stimulation of skeletal muscle, the insulin signaling pathway is activated. Akt is a critical node in the insulin signaling pathway and mediates most of the metabolic functions of insulin on skeletal muscle (Taniguchi et al. 2006). Akt is phosphorylated on threonine 308 in the activation loop by 3-phosphoinositide-dependent protein kinase 1 (PDK1) thereby enhancing the activity of the Akt kinase (Alessi et al. 1997). Our observation of a decreased insulin-stimulated phosphorylation of Akt\(^{\text{thr308}}\) in HIV-infected lipodystrophic patients compared to control subjects, indicate that the lower glucose uptake in HIV-infected patients is caused by defects involving PDK1 activation of Akt. This finding is in accordance with a study before and after the insulin clamp, but none of the insulin-stimulated activities were different between HIV-infected patients and controls. In support of this finding, phosphorylation of GSK-3\(^{\text{ser9}}\) and GS at site 3a+b, which has been previously reported to be affected by HIV lipodystrophy (Hauggaard et al. 2005), was comparable between groups in our study.

We observed an increased expression of Akt in skeletal muscle of HIV-infected patients following 16 weeks of endurance training. Of note, our endurance exercise protocol consisted of interval training and it is possible that steady state endurance exercise training would not have this effect on Akt expression. An increased protein expression of Akt following training has previously been observed in older subjects with and without Type 2 diabetes (Christ-Roberts et al. 2004) and in young healthy men (Frosig et al. 2007).

The increased Akt protein expression was not accompanied by changes in the phosphorylation status of Akt\(^{\text{thr308}}\). Nonetheless, an increased Akt protein expression could facilitate enhanced downstream Akt signaling reflected by changes in Akt activity without changes in phosphorylation of Akt\(^{\text{thr308}}\) (Frosig et al. 2007). Unfortunately, due to limited tissue availability, we were unable to measure Akt activity so we analyzed downstream Akt signaling. Akt signaling in skeletal muscle leads to phosphorylation of GSK3\(^{\text{ser9}}\), whereby the GSK enzyme is inactivated (Welsh and Proud 1993). This leads to dephosphorylation of GS site 3a+b, which subsequently activates the GS enzyme (McManus et al. 2005). We found no changes in the phosphorylation sites of these proteins or in the activity of GS following insulin stimulation. Thus, we have no indications that an increased Akt protein expression facilitated insulin signaling to glycogen synthesis. Neither did we observe changes in the phosphorylation state of AS160\(^{\text{ser422}}\) following the endurance training period. Thus, we did not identify a pathway whereby increased Akt protein expression would enhance insulin-stimulated glucose uptake. Interestingly, total GS activity increased with endurance training as observed both with and without insulin stimulation. This adaptation is a consistent result of changes in Akt activation and downstream signaling.

Regimes and euglycemic–hyperinsulinemic clamps with molecular analyses in muscle biopsies.

Upon insulin stimulation of skeletal muscle, the insulin signaling pathway is activated. Akt is a critical node in the insulin signaling pathway and mediates most of the metabolic functions of insulin on skeletal muscle (Taniguchi et al. 2006). Akt is phosphorylated on threonine 308 in the activation loop by 3-phosphoinositide-dependent protein kinase 1 (PDK1) thereby enhancing the activity of the Akt kinase (Alessi et al. 1997). Our observation of a decreased insulin-stimulated phosphorylation of Akt\(^{\text{thr308}}\) in HIV-infected lipodystrophic patients compared to control subjects, indicate that the lower glucose uptake in HIV-infected patients is caused by defects involving PDK1 activation of Akt. This finding is in accordance with a study before and after the insulin clamp, but none of the insulin-stimulated activities were different between HIV-infected patients and controls. In support of this finding, phosphorylation of GSK-3\(^{\text{ser9}}\) and GS at site 3a+b, which has been previously reported to be affected by HIV lipodystrophy (Hauggaard et al. 2005), was comparable between groups in our study.

We observed an increased expression of Akt in skeletal muscle of HIV-infected patients following 16 weeks of endurance training. Of note, our endurance exercise protocol consisted of interval training and it is possible that steady state endurance exercise training would not have this effect on Akt expression. An increased protein expression of Akt following training has previously been observed in older subjects with and without Type 2 diabetes (Christ-Roberts et al. 2004) and in young healthy men (Frosig et al. 2007).

The increased Akt protein expression was not accompanied by changes in the phosphorylation status of Akt\(^{\text{thr308}}\). Nonetheless, an increased Akt protein expression could facilitate enhanced downstream Akt signaling reflected by changes in Akt activity without changes in phosphorylation of Akt\(^{\text{thr308}}\) (Frosig et al. 2007). Unfortunately, due to limited tissue availability, we were unable to measure Akt activity so we analyzed downstream Akt signaling. Akt signaling in skeletal muscle leads to phosphorylation of GSK3\(^{\text{ser9}}\), whereby the GSK enzyme is inactivated (Welsh and Proud 1993). This leads to dephosphorylation of GS site 3a+b, which subsequently activates the GS enzyme (McManus et al. 2005). We found no changes in the phosphorylation sites of these proteins or in the activity of GS following insulin stimulation. Thus, we have no indications that an increased Akt protein expression facilitated insulin signaling to glycogen synthesis. Neither did we observe changes in the phosphorylation state of AS160\(^{\text{ser422}}\) following the endurance training period. Thus, we did not identify a pathway whereby increased Akt protein expression would enhance insulin-stimulated glucose uptake. Interestingly, total GS activity increased with endurance training as observed both with and without insulin stimulation. This adaptation is a consistent result of changes in Akt activation and downstream signaling.
finding following training regimes (Christ-Roberts et al. 2004; Holten et al. 2004; Frosig et al. 2007), but does not seem to result from changes in insulin signaling.

Both AMPK and PGC1α have been shown to be involved in the beneficial effects of endurance exercise on metabolism in skeletal muscle (Olesen et al. 2010; Hardie 2011). Due to limited sample availability we were unable to examine these pathways in the present study. But the possibility exist that AMPK and PGC1α contribute to the improved glucose regulation observed in the HIV patients undergoing endurance exercise.

Both endurance and strength training increased protein expression of HKII in skeletal muscle of HIV-infected patients. Increased HKII protein expression has previously been reported following endurance and strength training (Phillips et al. 1996; Frosig et al. 2007) and may be involved in the improved glucose metabolism following training. Control of glucose uptake is distributed between three steps: the rate that glucose is delivered to cells, the rate of transport into cells, and the rate that glucose is metabolized within the cells (Wasserman and Ayala 2005). An increased protein expression of HKII may facilitate faster intracellular glucose metabolism by phosphorylation of glucose to glucose-6 phosphate and thereby increase the rate of glucose metabolism within the muscle cells (Petersen and Shulman 2002; Wasserman and Ayala 2005). Indeed, overexpression of HKII in rodent skeletal muscle resulted in increased insulin-stimulated glucose uptake in vivo (Halseth et al. 1999; Fueger et al. 2005). Thus, the overexpression HKII, rather than changes in markers of insulin signaling or affected GS activity. However, both endurance and strength training increased protein expression HKII, thereby showing that training adaptation in HIV-infected patients is associated with improved capacity for phosphorylation of glucose by HKII, rather than changes in markers of insulin signaling to glucose uptake or glycogen synthesis.

**Conflict of Interest**

None declared.

**References**

Alessi, D. R., S. R. James, C. P. Downes, A. B. Holmes, P. R. Gaffney, C. B. Reese, et al. 1997. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balph. Curr. Biol. 7:261–269.

Andersen, O., S. B. Haugaard, U. B. Andersen, N. Friis-Moller, H. Storgaard, A. Volund, et al. 2003. Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function. Metabolism 52:1343–1353.

Astrand, I., P. O. Astrand, I. Hallback, and A. Kilbom. 1973. Reduction in maximal oxygen uptake with age. J. Appl. Physiol. 35:649–654.

Behrens, G. M., A. R. Boerner, K. Weber, J. van den Hoff, J. Ockenga, G. Brabant, et al. 2002. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J. Clin. Invest. 110:1319–1327.

Bergstrom, J. 1975. Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand. J. Clin. Lab. Invest. 35:609–616.

Christ-Roberts, C. Y., T. Pratipanawatr, W. Pratipanawatr, R. Berria, R. Belfort, S. Kashyap, et al. 2004. Exercise training increases glycogen synthase activity and GLUT4 expression but not insulin signaling in overweight nondiabetic and type 2 diabetic subjects. Metabolism 53:1233–1242.

Dolan, S. E., W. Frontera, J. Librizzi, K. Ljunquist, S. Juan, R. Dorman, et al. 2006. Effects of a supervised home-based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus: a randomized trial. Arch. Intern. Med. 166:1225–1231.

Driscoill, S. D., G. E. Meininger, M. T. Lareau, S. E. Dolan, K. M. Killilea, C. M. Hadigan, et al. 2004. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 18:465–473.

Frosig, C., A. J. Rose, J. T. Treebak, B. Kiens, E. A. Richter, and J. F. Wojtaszewski. 2007. Effects of endurance exercise training on insulin signaling in human skeletal muscle: interactions at the level of phosphatidylinositol 3-kinase, Akt, and AS160. Diabetes 56:2093–2102.

Fueger, P. T., J. Shearer, D. P. Bracy, K. A. Posey, R. R. Pencek, O. P. McGuinness, et al. 2005. Control of muscle glucose uptake: test of the rate-limiting step paradigm in conscious, unrestrained mice. J. Physiol. 562:925–935.

Grinspoon, S., and A. Carr. 2005. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N. Engl. J. Med. 352:48–62.

Halseth, A. E., D. P. Bracy, and D. H. Wasserman. 1999. Overexpression of hexokinase II increases insulinand exercise-stimulated muscle glucose uptake in vivo. Am. J. Physiol. 276:E70–E77.
Hardie, D. G. 2011. Energy sensing by the AMP-activated protein kinase and its effects on muscle metabolism. Proc. Nutr. Soc. 70:92–99.

Haugaard, S. B., O. Andersen, S. Madsbad, C. Froslig, J. Iversen, J. O. Nielsen, et al. 2005. Skeletal muscle insulin signaling defects downstream of phosphatidylinositol 3-kinase at the level of Akt are associated with impaired nonoxidative glucose disposal in HIV lipodystrophy. Diabetes 54:3474–3483.

Hawley, J. A. 2004. Exercise as a therapeutic intervention for the prevention and treatment of insulin resistance. Diabetes Metab. Res. Rev. 20:383–393.

Henriksen, E. J. 2002. Invited review: effects of acute exercise and exercise training on insulin resistance. J. Appl. Physiol. 93:788–796.

Holten, M. K., M. Zacho, M. Gaster, C. Juel, J. F. Wojtaszewski, and F. Dela. 2004. Strength training increases insulin-mediated glucose uptake, GLUT4 content, and insulin signaling in skeletal muscle in patients with type 2 diabetes. Diabetes 53:294–305.

Jones, S. P., D. A. Doran, P. B. Leatt, B. Maher, and M. Pirmohamed. 2001. Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. AIDS 15:2049–2051.

Karlsson, H. K., J. R. Zierath, S. Kane, A. Krook, G. E. Lienhard, and H. Wallberg-Henriksson. 2005. Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in skeletal muscle of type 2 diabetic subjects. Diabetes 54:1692–1697.

Lindegaard, B., T. Hansen, T. Hvid, G. van Hall, P. Plomgaard, S. Ditlevsen, et al. 2008. The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. J. Clin. Endocrinol. Metab. 93:3860–3869.

Olesen, J., K. Kølstrup, and H. Pilegaard. 2010. PGC-1alpha-mediated adaptations in skeletal muscle. Pflugers Arch. 460:153–162.

Pedersen, B. K. 2006. The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular disease control. Essays Biochem. 42:105–117.

Petersen, K. F., and G. I. Shulman. 2002. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am. J. Cardiol. 90:11G–18G.

Phillips, S. M., X. X. Han, H. J. Green, and A. Bonen. 1996. Increments in skeletal muscle GLUT-1 and GLUT-4 after endurance training in humans. Am. J. Physiol. 270:E456–E462.

Ramm, G., M. Larance, M. Guilhaus, and D. E. James. 2006. A role for 14-3-3 in insulin-stimulated GLUT4 translocation through its interaction with the RabGAP AS160. J. Biol. Chem. 281:29174–29180.

Robinson, F. P., L. T. Quinn, and J. H. Rimmer. 2007. Effects of high-intensity endurance and resistance exercise on HIV metabolic abnormalities: a pilot study. Br. J. Nutr. 98:177–185.

Sano, H., S. Kane, E. Sano, C. P. Miinea, J. M. Asara, W. S. Lane, et al. 2003. Insulin-stimulated phosphorylation of a Rab GTase-activating protein regulates GLUT4 translocation. J. Biol. Chem. 278:14599–14602.

Shulman, G. I., D. L. Rothman, T. Jue, P. Stein, R. A. DeFronzo, and R. G. Shulman. 1990. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N. Engl. J. Med. 322:223–228.

Smith, B. A., J. L. Neidig, J. T. Nickel, G. L. Mitchell, M. F. Para, and R. J. Fass. 2001. Aerobic exercise: effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults. AIDS 15:693–701.

Takiguchi, C. M., B. Emanuelli, and C. R. Kahn. 2006. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7:85–96.

Thomas, J. A., K. K. Schlender, and J. Larner. 1968. A rapid filter paper assay for UDPglucose-glycogen glucosyltransferase, including an improved biosynthesis of UDP-14C-glucone. Anal. Biochem. 25:486–499.

Thoni, G. J., C. Fedou, J. F. Brun, J. Fabre, E. Renard, J. A. Reyens, et al. 2002. Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. Diabetes Metab. 28:397–404.

van der Valk, M., P. H. Bisschop, J. A. Romijn, M. T. Ackermans, J. M. Lange, E. Endert, et al. 2001. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 15:2093–2100.

Wasserman, D. H., and J. E. Ayala. 2005. Interaction of physiological mechanisms in control of muscle glucose uptake. Clin. Exp. Pharmacol. Physiol. 32:319–323.

Welsh, G. L., and C. G. Proud. 1993. Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem. J. 294:625–629.

Yarasheski, K. E., P. Tebas, B. Stanerson, S. Claxton, D. Marin, K. Bae, et al. 2001. Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J. Appl. Physiol. 90:133–138.

Zierath, J. R. 2002. Invited review: exercise training-induced changes in insulin signaling in skeletal muscle. J. Appl. Physiol. 93:773–781.